Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | NPY4R | P50391 | 4/20 | 0.39 |
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24028236 | 1.00 | FAP (0.42) | FAPTRPV1NPY5RNPY4RNPY1R | |
| SCHEMBL24500888 | 0.98 | FAP (0.40) | FAPTRPV1NPY5RNPY4RNPY1R | |
| SCHEMBL27421377 | 0.95 | FAP (0.46) | FAPTRPV1NPY5RNPY4RNPY1R | |
| SCHEMBL27433100 | 0.94 | FAP (0.46) | FAPTRPV1NPY5RNPY4RNPY1R | |
| SCHEMBL27433756 | 0.94 | FAP (0.46) | FAPTRPV1NPY5RNPY4RNPY1R | |
| SCHEMBL27421384 | 0.94 | FAP (0.46) | FAPTRPV1NPY5RNPY4RNPY1R | |
| SCHEMBL21649698 | 0.93 | FURIN (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22336596 | 0.93 | FURIN (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18244334 | 0.93 | FAP (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18244335 | 0.93 | FAP (0.40) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-20210283267-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | VOR BIOPHARMA, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD40LG, CD44, CD74 | FAP 3392/4885TRPV1 4397/4885NPY5R 3252/4885 |
| US-20210283267-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | CD44, FCGR1A, FCGR3B | FAP 3637/4885TRPV1 4822/4885NPY5R 3895/4885 |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | FAP 1883/4885TRPV1 4578/4885NPY5R 4027/4885 |
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD59, CD58, CD2 | FAP 3211/4885TRPV1 2565/4885NPY5R 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.